Cincinnati Children's

CompanyUnited States

Cincinnati Children's develops one asset, in human trials (lunsotogene parvec-cwha in inherited deafness). Mostly gene therapy acting on OTOF; based in the United States.

1
Asset
Furthest stage: Human trials; 0
Trials: 0
Signals

Pipeline

1

lunsotogene parvec-cwha
Adeno-associated virus gene therapy delivering a functional copy of the otoferlin gene
Human trials, Gene therapy, OTOF, inherited deafness

Full company profiles: pipeline, trials, funding and people.

In the full profile

Integrity notices6